Sildenafil for Pulmonary Hypertension associated with Congenital Heart Defect
The Internet Journal of Pediatrics and Neonatology · 2007
DOI: 10.5580/1334 ↗At a glance
Journal article in The Internet Journal of Pediatrics and Neonatology, 2007.
Abstract (original language)
Background
Pulmonary hypertension (PH) when associated with congenital heart defects (CHD) carries high post-operative mortality. Various pulmonary vasodilators have been used in such a situation. Our experience of using sildenafil, an affordable option in resource – limited setting, is described in this study.
Objective
To study pulmonary artery pressure (PAP) before and after siladenafil in cases of CHD. Study design: A case series observational in nature.
Methods
The subjects were 12 neonates and 11 infants. Their mode of presentation was studied. Echocardiography was performed before and after treatment.
Results
Sixteen patients presented with respiratory distress, three with oxygen dependence, three had hypoxaemia disproportionate to pulmonary or cardiac problem and one was asymptomatic. In seven cases, PH was detected during echo performed for suspected CHD. After sildenafil, PAP normalized in six cases, substantially declined in eight, and remained unchanged in nine. The response was better among babies less than two months old.
Conclusion
Sildenafil is effective in the treatment of PH associated with CHD. Oral availability and low cost are valuable considerations in resource-limited setting.
Cite
APA
(2007). Sildenafil for Pulmonary Hypertension associated with Congenital Heart Defect. The Internet Journal of Pediatrics and Neonatology. https://doi.org/10.5580/1334
Vancouver
Sildenafil for Pulmonary Hypertension associated with Congenital Heart Defect. The Internet Journal of Pediatrics and Neonatology. 2007. doi:10.5580/1334
BibTeX
@article{euvimed2007,
title = {Sildenafil for Pulmonary Hypertension associated with Congenital Heart Defect},
journal = {The Internet Journal of Pediatrics and Neonatology},
year = {2007},
doi = {10.5580/1334}
}
EUVIMED